OBJECTIVE: This study was performed to examine both brain and systemic interleukin-6 (IL-6) release in patients with an acute brain injury (ABI), to study whether a correlation exists between the transcranial IL-6 gradient during the first days after injury and prognosis, and finally, to investigate the relationship between a nucleotide polymorphism at position -174 in the promoter of the gene encoding IL-6, IL-6 responsiveness, and clinical evolution. DESIGN: Prospective clinical investigation. SETTING: A 19-bed intensive care unit in a university hospital. PATIENTS AND METHODS: A total of 62 patients were followed up for 3 days after acute brain injury, and both their arterial and jugular IL-6 levels were measured serially and at the moment of brain death diagnosis. Genetic polymorphism of IL-6 was also determined in all patients. Data were correlated with those from score procedures for clinical severity. Neurologic outcome was graded according to the Glasgow Outcome Scale 6 months after injury. IL-6 levels and IL-6 genotyping was performed in control healthy individuals. MAIN RESULTS: There is a significant transcranial IL-6 gradient at admission and at the moment of brain death. The gradient is higher in those patients who evolved toward a fatal outcome during the first 6 months after injury (p <.001). There is significant correlation between the transcranial IL-6 gradient and the acute brain injury severity. CONCLUSIONS: IL-6 is elevated in patients with acute brain injury, and a significant relationship exits between the severity of acute brain injury and the transcranial IL-6 gradient at admission. It can be considered to be a prognosis marker at admission. When data at the moment of brain death are considered, venous IL-6 (p <.01) and the transcranial IL-6 gradient (p <.005) are significantly higher than at the time of admission. Although the IL-6 C allele is associated with significantly lower concentrations of IL-6, there was no correlation between low or high IL-6 responders and patient outcome.
OBJECTIVE: This study was performed to examine both brain and systemic interleukin-6 (IL-6) release in patients with an acute brain injury (ABI), to study whether a correlation exists between the transcranial IL-6 gradient during the first days after injury and prognosis, and finally, to investigate the relationship between a nucleotide polymorphism at position -174 in the promoter of the gene encoding IL-6, IL-6 responsiveness, and clinical evolution. DESIGN: Prospective clinical investigation. SETTING: A 19-bed intensive care unit in a university hospital. PATIENTS AND METHODS: A total of 62 patients were followed up for 3 days after acute brain injury, and both their arterial and jugular IL-6 levels were measured serially and at the moment of brain death diagnosis. Genetic polymorphism of IL-6 was also determined in all patients. Data were correlated with those from score procedures for clinical severity. Neurologic outcome was graded according to the Glasgow Outcome Scale 6 months after injury. IL-6 levels and IL-6 genotyping was performed in control healthy individuals. MAIN RESULTS: There is a significant transcranial IL-6 gradient at admission and at the moment of brain death. The gradient is higher in those patients who evolved toward a fatal outcome during the first 6 months after injury (p <.001). There is significant correlation between the transcranial IL-6 gradient and the acute brain injury severity. CONCLUSIONS:IL-6 is elevated in patients with acute brain injury, and a significant relationship exits between the severity of acute brain injury and the transcranial IL-6 gradient at admission. It can be considered to be a prognosis marker at admission. When data at the moment of brain death are considered, venous IL-6 (p <.01) and the transcranial IL-6 gradient (p <.005) are significantly higher than at the time of admission. Although the IL-6 C allele is associated with significantly lower concentrations of IL-6, there was no correlation between low or high IL-6 responders and patient outcome.
Authors: Sung H Yang; Josh Gustafson; Matt Gangidine; David Stepien; Rebecca Schuster; Timothy A Pritts; Michael D Goodman; Daniel G Remick; Alex B Lentsch Journal: J Surg Res Date: 2013-04-18 Impact factor: 2.192
Authors: Maria Angeles Ballesteros; Marcos López-Hoyos; Pedro Muñoz; Maria Jose Marin; Eduardo Miñambres Journal: Intensive Care Med Date: 2006-09-09 Impact factor: 17.440
Authors: Eduardo Miñambres; Herminio Lopez-Escribano; María A Ballesteros; Marta Peña; Marcos López-Hoyos Journal: Intensive Care Med Date: 2005-04-21 Impact factor: 17.440
Authors: Georgene W Hergenroeder; Anthony N Moore; J Philip McCoy; Leigh Samsel; Norman H Ward; Guy L Clifton; Pramod K Dash Journal: J Neuroinflammation Date: 2010-03-11 Impact factor: 8.322